Incyte (NASDAQ:INCY – Get Free Report) is scheduled to issue its quarterly earnings data before the market opens on Tuesday, April 30th. Analysts expect the company to announce earnings of $0.87 per share for the quarter. Parties interested in participating in the company’s conference call can do so using this link.
Incyte (NASDAQ:INCY – Get Free Report) last posted its quarterly earnings results on Tuesday, February 13th. The biopharmaceutical company reported $1.06 earnings per share for the quarter, missing analysts’ consensus estimates of $1.15 by ($0.09). The company had revenue of $1.01 billion during the quarter, compared to analyst estimates of $1 billion. Incyte had a net margin of 16.17% and a return on equity of 12.56%. The business’s revenue for the quarter was up 9.3% compared to the same quarter last year. During the same period last year, the company earned $0.44 EPS. On average, analysts expect Incyte to post $4 EPS for the current fiscal year and $5 EPS for the next fiscal year.
Incyte Stock Performance
Shares of Incyte stock opened at $51.92 on Tuesday. The company has a market capitalization of $11.66 billion, a PE ratio of 19.59, a PEG ratio of 1.21 and a beta of 0.65. Incyte has a 12 month low of $50.27 and a 12 month high of $75.74. The company has a current ratio of 3.55, a quick ratio of 3.36 and a debt-to-equity ratio of 0.01. The stock’s fifty day simple moving average is $57.34 and its 200 day simple moving average is $57.86.
Analyst Upgrades and Downgrades
Check Out Our Latest Stock Analysis on INCY
Incyte Company Profile
Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for hematology/oncology, and inflammation and autoimmunity areas in the United States and internationally. The company offers JAKAFI (ruxolitinib) for treatment of intermediate or high-risk myelofibrosis, polycythemia vera, and steroid-refractory acute graft-versus-host disease; MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab) for relapsed or refractory diffuse large B-cell lymphoma; PEMAZYRE (pemigatinib), a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in liquid and solid tumor types; ICLUSIG (ponatinib) to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; and ZYNYZ (retifanlimab-dlwr) to treat adults with metastatic or recurrent locally advanced Merkel cell carcinoma, as well as OPZELURA cream for treatment of atopic dermatitis.
Featured Stories
- Five stocks we like better than Incyte
- The Top 3 Healthcare Dividend Stocks to Buy and Hold
- It’s Time to Buy Into the Super Micro Computer Stock Implosion
- The Most Important Warren Buffett Stock for Investors: His Own
- Merger or Not, Albertson’s Companies is a Good Buy
- How to Calculate Inflation Rate
- 3 Cheap Stocks That Shouldn’t Be So
Receive News & Ratings for Incyte Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Incyte and related companies with MarketBeat.com's FREE daily email newsletter.